Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

February 14, 2001 14 February, 2001

Pheromone Sciences Corp Adds Half Warrant To Offering Pheromone Sciences Corp Adds Half Warrant To Offering

Pheromone Sciences Corp. (CDNX:PHS) today announced that its recently announced $2.2 million special warrant private placement has been amended, subject to regulatory approval, to provide that each special warrant of the Company will be exercisable, at no additional consideration, into one common share and one-half of a warrant. Each whole warrant will entitle the holder to purchase one common share of the Company at an exercise price of $1.25 per share for one year from closing anticipated for February, 2001.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.